Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents

Yann Ferrand, Christina M.L. Kelton, Jeff J. Guo, Martin S. Levy, Yan Yu

Research output: Contribution to journalArticle

Abstract

Background: Medicaid programs' spending on antidepressants increased from $159 million in 1991 to $2 billion in 2005. The National Institute for Health Care Management attributed this expenditure growth to increases in drug utilization, entry of newer higher-priced antidepressants, and greater prescription drug insurance coverage. Rising enrollment in Medicaid has also contributed to this expenditure growth. Objectives: This research examines the impact of specific events, including branded-drug and generic entry, a black box warning, direct-to-consumer advertising (DTCA), and new indication approval, on Medicaid spending on antidepressants. Methods: Using quarterly expenditure data for 1991-2005 from the national Medicaid pharmacy claims database maintained by the Centers for Medicare and Medicaid Services, a time-series autoregressive integrated moving average (ARIMA) intervention analysis was performed on 6 specific antidepressant drugs and on overall antidepressant spending. Twenty-nine potentially relevant interventions and their dates of occurrence were identified from the literature. Each was tested for an impact on the time series. Forecasts from the models were compared with a holdout sample of actual expenditure data. Results: Interventions with significant impacts on Medicaid expenditures included the patent expiration of Prozac. ® (P<0.01) and the entry of generic paroxetine producers (P=0.04), which reduced expenditures on Prozac. ® and Paxil. ®, respectively, and the 1997 increase in DTCA (P=0.05), which increased spending on Wellbutrin. ®. Except for Paxil. ®, the ARIMA models had low prediction errors. Conclusions: Generic entry at the aggregate level did not lead to a reduction in overall expenditures (P>0.05), implying that the expanding market for antidepressants overwhelmed the effect of generic competition.

Original languageEnglish (US)
Pages (from-to)64-80
Number of pages17
JournalResearch in Social and Administrative Pharmacy
Volume7
Issue number1
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Time series analysis
Medicaid
Health Expenditures
Antidepressive Agents
Pharmaceutical Services Insurance
Time series
Drug Labeling
Generic Drugs
Drug Utilization
Centers for Medicare and Medicaid Services (U.S.)
Insurance Coverage
Prescription Drugs
Fluoxetine
National Institutes of Health (U.S.)
Insurance
Growth
Health care
Marketing
Databases
Delivery of Health Care

Keywords

  • Antidepressant drugs
  • Direct-to-consumer advertising
  • Forecasting
  • Generic entry
  • Medicaid expenditures
  • Time-series intervention analysis

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science

Cite this

Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents. / Ferrand, Yann; Kelton, Christina M.L.; Guo, Jeff J.; Levy, Martin S.; Yu, Yan.

In: Research in Social and Administrative Pharmacy, Vol. 7, No. 1, 01.03.2011, p. 64-80.

Research output: Contribution to journalArticle

Ferrand, Yann ; Kelton, Christina M.L. ; Guo, Jeff J. ; Levy, Martin S. ; Yu, Yan. / Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents. In: Research in Social and Administrative Pharmacy. 2011 ; Vol. 7, No. 1. pp. 64-80.
@article{1f9e436aabbc4f8da24b400aaf9ece2a,
title = "Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents",
abstract = "Background: Medicaid programs' spending on antidepressants increased from $159 million in 1991 to $2 billion in 2005. The National Institute for Health Care Management attributed this expenditure growth to increases in drug utilization, entry of newer higher-priced antidepressants, and greater prescription drug insurance coverage. Rising enrollment in Medicaid has also contributed to this expenditure growth. Objectives: This research examines the impact of specific events, including branded-drug and generic entry, a black box warning, direct-to-consumer advertising (DTCA), and new indication approval, on Medicaid spending on antidepressants. Methods: Using quarterly expenditure data for 1991-2005 from the national Medicaid pharmacy claims database maintained by the Centers for Medicare and Medicaid Services, a time-series autoregressive integrated moving average (ARIMA) intervention analysis was performed on 6 specific antidepressant drugs and on overall antidepressant spending. Twenty-nine potentially relevant interventions and their dates of occurrence were identified from the literature. Each was tested for an impact on the time series. Forecasts from the models were compared with a holdout sample of actual expenditure data. Results: Interventions with significant impacts on Medicaid expenditures included the patent expiration of Prozac. {\circledR} (P<0.01) and the entry of generic paroxetine producers (P=0.04), which reduced expenditures on Prozac. {\circledR} and Paxil. {\circledR}, respectively, and the 1997 increase in DTCA (P=0.05), which increased spending on Wellbutrin. {\circledR}. Except for Paxil. {\circledR}, the ARIMA models had low prediction errors. Conclusions: Generic entry at the aggregate level did not lead to a reduction in overall expenditures (P>0.05), implying that the expanding market for antidepressants overwhelmed the effect of generic competition.",
keywords = "Antidepressant drugs, Direct-to-consumer advertising, Forecasting, Generic entry, Medicaid expenditures, Time-series intervention analysis",
author = "Yann Ferrand and Kelton, {Christina M.L.} and Guo, {Jeff J.} and Levy, {Martin S.} and Yan Yu",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.sapharm.2009.12.002",
language = "English (US)",
volume = "7",
pages = "64--80",
journal = "Research in Social and Administrative Pharmacy",
issn = "1551-7411",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents

AU - Ferrand, Yann

AU - Kelton, Christina M.L.

AU - Guo, Jeff J.

AU - Levy, Martin S.

AU - Yu, Yan

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Medicaid programs' spending on antidepressants increased from $159 million in 1991 to $2 billion in 2005. The National Institute for Health Care Management attributed this expenditure growth to increases in drug utilization, entry of newer higher-priced antidepressants, and greater prescription drug insurance coverage. Rising enrollment in Medicaid has also contributed to this expenditure growth. Objectives: This research examines the impact of specific events, including branded-drug and generic entry, a black box warning, direct-to-consumer advertising (DTCA), and new indication approval, on Medicaid spending on antidepressants. Methods: Using quarterly expenditure data for 1991-2005 from the national Medicaid pharmacy claims database maintained by the Centers for Medicare and Medicaid Services, a time-series autoregressive integrated moving average (ARIMA) intervention analysis was performed on 6 specific antidepressant drugs and on overall antidepressant spending. Twenty-nine potentially relevant interventions and their dates of occurrence were identified from the literature. Each was tested for an impact on the time series. Forecasts from the models were compared with a holdout sample of actual expenditure data. Results: Interventions with significant impacts on Medicaid expenditures included the patent expiration of Prozac. ® (P<0.01) and the entry of generic paroxetine producers (P=0.04), which reduced expenditures on Prozac. ® and Paxil. ®, respectively, and the 1997 increase in DTCA (P=0.05), which increased spending on Wellbutrin. ®. Except for Paxil. ®, the ARIMA models had low prediction errors. Conclusions: Generic entry at the aggregate level did not lead to a reduction in overall expenditures (P>0.05), implying that the expanding market for antidepressants overwhelmed the effect of generic competition.

AB - Background: Medicaid programs' spending on antidepressants increased from $159 million in 1991 to $2 billion in 2005. The National Institute for Health Care Management attributed this expenditure growth to increases in drug utilization, entry of newer higher-priced antidepressants, and greater prescription drug insurance coverage. Rising enrollment in Medicaid has also contributed to this expenditure growth. Objectives: This research examines the impact of specific events, including branded-drug and generic entry, a black box warning, direct-to-consumer advertising (DTCA), and new indication approval, on Medicaid spending on antidepressants. Methods: Using quarterly expenditure data for 1991-2005 from the national Medicaid pharmacy claims database maintained by the Centers for Medicare and Medicaid Services, a time-series autoregressive integrated moving average (ARIMA) intervention analysis was performed on 6 specific antidepressant drugs and on overall antidepressant spending. Twenty-nine potentially relevant interventions and their dates of occurrence were identified from the literature. Each was tested for an impact on the time series. Forecasts from the models were compared with a holdout sample of actual expenditure data. Results: Interventions with significant impacts on Medicaid expenditures included the patent expiration of Prozac. ® (P<0.01) and the entry of generic paroxetine producers (P=0.04), which reduced expenditures on Prozac. ® and Paxil. ®, respectively, and the 1997 increase in DTCA (P=0.05), which increased spending on Wellbutrin. ®. Except for Paxil. ®, the ARIMA models had low prediction errors. Conclusions: Generic entry at the aggregate level did not lead to a reduction in overall expenditures (P>0.05), implying that the expanding market for antidepressants overwhelmed the effect of generic competition.

KW - Antidepressant drugs

KW - Direct-to-consumer advertising

KW - Forecasting

KW - Generic entry

KW - Medicaid expenditures

KW - Time-series intervention analysis

UR - http://www.scopus.com/inward/record.url?scp=79952627453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952627453&partnerID=8YFLogxK

U2 - 10.1016/j.sapharm.2009.12.002

DO - 10.1016/j.sapharm.2009.12.002

M3 - Article

C2 - 21397882

AN - SCOPUS:79952627453

VL - 7

SP - 64

EP - 80

JO - Research in Social and Administrative Pharmacy

JF - Research in Social and Administrative Pharmacy

SN - 1551-7411

IS - 1

ER -